[Fractures and bone mineral density in childhood].
Frakturen und Knochendichte im Kindesalter.
Anti-inflammatory drugs
Fracture risk
Inflammatory joint diseases
Juvenile idiopathic arthritis
Medicinal prevention
Journal
Zeitschrift fur Rheumatologie
ISSN: 1435-1250
Titre abrégé: Z Rheumatol
Pays: Germany
ID NLM: 0414162
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
25
7
2019
medline:
8
10
2019
entrez:
25
7
2019
Statut:
ppublish
Résumé
In juvenile idiopathic arthritis and related chronic inflammatory diseases, proinflammatory cytokines inhibit bone formation and stimulate bone resorption. Anti-inflammatory drugs, such as glucocorticoids and nonsteroidal antirheumatic drugs (NSARD) have as a side effect the potential to inhibit growth and maintenance of bone. These issues are of particular importance for the growing skeleton in childhood and adolescence. This article presents a narrative overview about the dimension of the problem, a critical evaluation of diagnostic procedures and a discussion of available countermeasures. A systematic literature search was carried out and the available evidence was evaluated based on the authors' knowledge and clinical experience as experts in the field. In recent years solid data have been accumulated with respect to the interpretation of bone mineral density (BMD) measurements in children and adolescents. Based on these data from the literature and given that the radiation exposure is also very low, it is now possible to clinically apply BMD measurements in this population using dual energy X‑ray absorption (DXA) technology for risk evaluation and diagnosis, taking the respective phase of development and body length into consideration. Dynamic measurements over time appear to be especially valuable in the context of individual clinical data. Hence, BMD measurements can be helpful in monitoring bone health, especially in juvenile idiopathic arthritis and other related inflammatory diseases. Apart from the specific indications for extended diagnostics and bone targeted pharmacological treatment, this method can also contribute to the management of preventive measures, such as sufficient calcium and vitamin D intake and targeted exercise interventions. Even in times of extremely effective antirheumatic drugs, children with chronic inflammatory diseases still bear a risk for bone health.
Sections du résumé
BACKGROUND
BACKGROUND
In juvenile idiopathic arthritis and related chronic inflammatory diseases, proinflammatory cytokines inhibit bone formation and stimulate bone resorption. Anti-inflammatory drugs, such as glucocorticoids and nonsteroidal antirheumatic drugs (NSARD) have as a side effect the potential to inhibit growth and maintenance of bone. These issues are of particular importance for the growing skeleton in childhood and adolescence.
OBJECTIVE
OBJECTIVE
This article presents a narrative overview about the dimension of the problem, a critical evaluation of diagnostic procedures and a discussion of available countermeasures.
METHODS
METHODS
A systematic literature search was carried out and the available evidence was evaluated based on the authors' knowledge and clinical experience as experts in the field.
RESULTS AND CONCLUSION
CONCLUSIONS
In recent years solid data have been accumulated with respect to the interpretation of bone mineral density (BMD) measurements in children and adolescents. Based on these data from the literature and given that the radiation exposure is also very low, it is now possible to clinically apply BMD measurements in this population using dual energy X‑ray absorption (DXA) technology for risk evaluation and diagnosis, taking the respective phase of development and body length into consideration. Dynamic measurements over time appear to be especially valuable in the context of individual clinical data. Hence, BMD measurements can be helpful in monitoring bone health, especially in juvenile idiopathic arthritis and other related inflammatory diseases. Apart from the specific indications for extended diagnostics and bone targeted pharmacological treatment, this method can also contribute to the management of preventive measures, such as sufficient calcium and vitamin D intake and targeted exercise interventions. Even in times of extremely effective antirheumatic drugs, children with chronic inflammatory diseases still bear a risk for bone health.
Identifiants
pubmed: 31338681
doi: 10.1007/s00393-019-0671-2
pii: 10.1007/s00393-019-0671-2
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
636-644Références
Bone Rep. 2018 Jan 28;8:38-45
pubmed: 29955621
J Bone Miner Res. 2018 Jan;33(1):42-53
pubmed: 28884881
Pediatrics. 2016 Oct;138(4):
pubmed: 27669735
Obes Rev. 2017 May;18(5):526-546
pubmed: 28273691
Pediatr Radiol. 2019 Mar;49(3):283-296
pubmed: 30421000
Bone. 2018 Aug;113:144-150
pubmed: 29800691
J Bone Miner Res. 2019 Jan;34(1):195-203
pubmed: 30372552
N Engl J Med. 2018 Dec 27;379(26):2547-2556
pubmed: 30586507
Arthritis Res Ther. 2014 Mar 31;16(2):R83
pubmed: 24684763
Clin Orthop Relat Res. 2018 Nov;476(11):2112-2122
pubmed: 30179948
Nat Rev Dis Primers. 2017 Aug 18;3:17052
pubmed: 28820180
Arthritis Care Res (Hoboken). 2019 Dec;71(12):1611-1620
pubmed: 30474929
Nat Rev Endocrinol. 2016 Apr;12(4):233-46
pubmed: 26893260
Bone. 2018 Jul;112:128-135
pubmed: 29679731
World J Clin Pediatr. 2018 Feb 8;7(1):43-48
pubmed: 29456931
Isr Med Assoc J. 2017 Sep;19(9):533-538
pubmed: 28971634
J Adolesc Health. 2019 Mar;64(3):305-310
pubmed: 30819332
Int J Eat Disord. 2019 May;52(5):591-596
pubmed: 30771231
Int J Eat Disord. 2017 Apr;50(4):359-369
pubmed: 28152193
J Bone Miner Res. 2015 Sep;30(9):1667-75
pubmed: 25801315
J Am Acad Dermatol. 2017 Jun;76(6):1045-1053.e3
pubmed: 28314685
Arch Osteoporos. 2018 Oct 29;13(1):117
pubmed: 30374788
Nat Rev Rheumatol. 2017 Feb;13(2):79-86
pubmed: 27974851
JAMA Pediatr. 2017 Sep 5;171(9):e171769
pubmed: 28672287
J Eat Disord. 2018 Nov 26;6:40
pubmed: 30534377
BMC Public Health. 2018 Nov 22;18(1):1285
pubmed: 30466435
Pediatr Rheumatol Online J. 2016 Nov 10;14(1):58
pubmed: 27832795
J Bone Miner Res. 2018 Mar;33(3):430-436
pubmed: 29068475
Semin Arthritis Rheum. 2016 Aug;46(1):49-63
pubmed: 27020068
Pediatr Exerc Sci. 2018 Nov 1;30(4):466-473
pubmed: 29804497
Nutrients. 2018 Dec 05;10(12):
pubmed: 30563066
J Bone Miner Res. 2017 Jan;32(1):172-180
pubmed: 27490028
Osteoporos Int. 2018 Dec;29(12):2667-2675
pubmed: 30128765
Osteoporos Sarcopenia. 2018 Jun;4(2):39-46
pubmed: 30775541
Curr Rheumatol Rep. 2004 Feb;6(1):70-8
pubmed: 14713405
J Clin Endocrinol Metab. 2019 Mar 1;104(3):892-899
pubmed: 30312423
Bone. 2019 Mar;120:452-458
pubmed: 30572143
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2735-2747
pubmed: 30811537
Pediatr Rheumatol Online J. 2018 Oct 22;16(1):67
pubmed: 30348221
J Pediatr. 2005 Jun;146(6):726-31
pubmed: 15973307